modelJ01RA16
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | CefiximeAndAzithromycin | |
| ATC code: | J01RA16 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 14 | L |
| clearance: | 1 | L/h |
| other parameters in model implementation | ||
Cefixime is a third-generation oral cephalosporin antibiotic, and azithromycin is a macrolide antibiotic. The fixed-dose combination is used primarily for the treatment of uncomplicated gonorrhea and other sexually transmitted infections due to their synergistic antibacterial effects. This combination is currently approved and in clinical use in several regions.
Pharmacokinetics
No published studies providing direct pharmacokinetic parameters for the fixed-dose combination of cefixime and azithromycin (J01RA16) were identified. The following values are estimated based on pharmacokinetic data for the individual drugs in healthy adults, given as a single oral dose.
References
Kong, FYS, et al., & Hocking, JS (2022). Optimisation of treatments for oral . BMJ open 12(11) e064782–None. DOI:10.1136/bmjopen-2022-064782 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36368750
Alonso, R, et al., & Canut, A (2021). Molecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment of . Pharmaceutics 13(10) –. DOI:10.3390/pharmaceutics13101699 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34683991
Jacobs, MR, et al., & Appelbaum, PC (1999). Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrobial agents and chemotherapy 43(8) 1901–1908. DOI:10.1128/AAC.43.8.1901 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10428910
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)